1. Home
  2. LMB vs XERS Comparison

LMB vs XERS Comparison

Compare LMB & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Limbach Holdings Inc.

LMB

Limbach Holdings Inc.

HOLD

Current Price

$72.72

Market Cap

1.2B

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.27

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMB
XERS
Founded
1901
2005
Country
United States
United States
Employees
1400
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
LMB
XERS
Price
$72.72
$6.27
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$116.67
$10.83
AVG Volume (30 Days)
310.6K
1.6M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
25.68
100.00
EPS
0.36
0.01
Revenue
$646,804,000.00
$49,590,000.00
Revenue This Year
$15.96
$34.37
Revenue Next Year
$5.90
$22.86
P/E Ratio
$207.75
$636.50
Revenue Growth
24.68
142.67
52 Week Low
$65.08
$4.30
52 Week High
$154.04
$10.08

Technical Indicators

Market Signals
Indicator
LMB
XERS
Relative Strength Index (RSI) 40.25 51.90
Support Level $71.40 $6.26
Resistance Level $85.38 $6.41
Average True Range (ATR) 6.95 0.28
MACD -2.73 0.00
Stochastic Oscillator 3.91 28.50

Price Performance

Historical Comparison
LMB
XERS

About LMB Limbach Holdings Inc.

Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: